Loading...
Market
Story
Pfizer's HYMPAVZI, First Once-Weekly Treatment for Hemophilia A and B Without Inhibitors, Approved by FDA
Oct 11, 2024, 06:18 PM
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq), a once-weekly subcutaneous injection, marking the first once-weekly hemophilia B treatment. The drug is approved for adults and adolescents aged 12 years and older with Hemophilia A without factor VIII inhibitors or Hemophilia B without factor IX inhibitors. HYMPAVZI™ is designed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with the two main types of hemophilia, a potentially deadly genetic disorder that impairs blood clotting. This approval represents Pfizer's second FDA approval for hemophilia in six months and is also the first FDA-approved hemophilia treatment that can be administered using a pre-filled auto-injector pen.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Less than $60 billion • 25%
$60 billion to $65 billion • 25%
$65 billion to $70 billion • 25%
More than $70 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
Less than $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
More than $12 billion • 25%
